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Summary 
As a first step towards standardization of assays measuring extracellular vesicle-associated 
tissue factor activity or tissue factor antigen of extracellular vesicles, information gathered 
from a questionnaire that was send to an expert panel was discussed at the 64
th
 Annual SSC 
Meeting of the ISTH (Dublin, Ireland). In addition, a SSC workshop initiative of Françoise 
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Dignat-George is summarized to compare the sensitivity and specificity of the currently used 
tissue factor assays. 
 
Introduction 
The clinical and scientific interest in extracellular vesicles (EVs) is growing exponentially. 
‘EVs’ is an umbrella term for various types of vesicles that are present in body fluids and 
other (bio)fluids. This umbrella term is used because clear hallmarks to distinguish different 
types of EVs from each other are lacking. Thus, the term ‘EVs’ encompasses earlier 
‘microparticles’ or ‘microvesicles’, and exosomes, which are vesicles released directly from 
the plasma membrane or by secretion of intraluminal vesicles stored in multivesicular 
endosomes, respectively [1, 2]. There is evidence that EVs play a role in intercellular 
communication, and contribute to coagulation and likely inflammation [3-6]. 
The oldest known function of “platelet dust”, now known as platelet-derived EVs, 
is their ability to support coagulation by exposing negatively-charged phospholipids, such 
as phosphatidylserine (PS). Such PS exposing EVs facilitates formation of tenase and 
prothrombinase complexes. 
 
 Furthermore, different subtypes of EVs, such as leukocyte, endothelial, or tumor-
derived EVs, can also trigger coagulation by exposing tissue factor (TF) [7].  TF exposing 
EVs (TF-EVs) are present in body fluids, such as saliva and urine under physiological 
conditions. The presence of TF-EVs in saliva may explain the reflex to lick a wound, 
thereby exposing blood to extravascular TF and accelerate haemostasis and reducing the 
risk of infection [8]. Although TF was initially thought to be exclusively present outside 
the vasculature (‘envelope model’), there is increasing evidence that during medical 
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intervention and in various clinical conditions, such as surgery or in patients suffering from 
sepsis or cancer, the presence of coagulant TF-EVs is associated with disseminated 
intravascular coagulation and venous thrombosis [9] [10].  
There are two reasons why a proposed standardization is timely and relevant. Firstly, 
there is a growing interest to improve the reproducibility of results in science in general, and 
this also holds true for the new field of EV research. During the last few years, “minimal 
requirements” have been published by the International Society of Extracellular Vesicles 
(ISEV) regarding the reporting on studies involving EVs [11-13], as well as a structure to 
record and score reporting of pre-analytical variables [14-17] In addition, guidelines and 
position papers have been published [18, 19]   and an increasing number of standardization 
studies have been and are being performed involving various aspects of EV detection and 
characterization [2, 14, 20, 21]. At present, various in-house and commercially available 
assays have been developed to measure the EV-associated TF (EV-TF) activity, but hitherto 
the results of these methods are not easily compared and require standardization. 
Secondly, to identify cancer patients at risk of developing venous thromboembolism 
(VTE), an EV-TF based factor Xa generation assay and an EV-TF based plasma clotting test 
have been developed and applied in clinical trials and have shown promising results for the 
prediction of VTE in pancreatic cancer patients. This underscores the relevance to study TF-
EVs as a potential clinically relevant biomarker [22, 23].  
Taken together, we provide a summary of the outcomes of the questionnaire and 
discussion with the goal to improve future standardization of studies measuring the TF 
activity of EVs.  
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Questionnaire and round table discussion of assays measuring the extracellular vesicle-
associated tissue factor activity 
A. Relevance of pre-analytical variables 
A number of variables were mentioned, including (i) anti-coagulant, (ii) time between blood 
collection and plasma preparation, (iii) the use of platelet-poor versus platelet-depleted 
plasma, and (iv) the use of fresh or frozen/thawed samples.  Although these variables have 
been studied in single and multicenter studies within the frame of the ISTH, there is a scarcity 
of data on the effects of pre-analytical variables on the EV-TF activity. All participants 
regarded ‘pre-analytics’ and development of ‘minimal requirements’ as relevant. 
 
Considerations and recommendations 
 There is a need to develop minimal requirements for pre-analytics to standardize assays 
measuring the EV-TF activity in plasmas. Currently available methodological guidelines 
can give orientation [14, 18]  
 There is a need for “easy” protocols in clinics (“complex protocols are also more likely to 
lead to  mistakes”) 
B. Assays used to measure the extracellular vesicle-associated tissue factor activity 
At present, different assays are being used to measure the EV-TF activity. The main 
differences are the use of (i) in-house or commercially available assays, (ii) assays sensitive 
to PS but not TF, TF, or both PS and TF, (iii) assays measuring factor Xa, thrombin activity, 
or fibrin formation, (iv) assays measuring the PCA of (endogenous) EVs directly in plasma, 
or, indirectly, by reconstituting isolated EVs in either pool plasma or incubating isolated EVs 
with purified coagulation factors, and (v) kinetic or “end-point” assays.  
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Considerations and recommendations 
 The duration of assays varies from < 20 minutes to 2 hours. There is no consensual 
position on the impact of duration on the analytical performances of these assays. 
 Presence or absence of tissue factor pathway inhibitor should be taken into account 
 Results from different assays may provide additional information and may be combined, 
but direct comparison is not recommended 
 Kinetic determination of the EV-TF dependent factor Xa generation rate may be more 
reproducible than a single end point measurement.  
  
 
C. Specificity of assays for tissue factor and phosphatidylserine 
To demonstrate the specificity for TF, participants use (i) an antibody against TF (clone HTF-
1), (ii) active site-inhibited factor VIIa (FVIIai), (iii) an antibody against factor VIIa, or (iv) 
TF-deficient EVs. The participant using FVIIai recommended FVIIai because of low cost and 
consistency. Whereas the main interest is focused on detection of TF-EVs, most participants 
were less certain about the sensitivity of their assays for PS.  
Considerations and recommendations 
 Anti-TF is preferred over anti-FVIIa antibody, because factor VIIa can activate factor X 
to Xa in the absence of TF [24] 
 Clone HTF-1 (anti-TF) is recommended to inhibit TF coagulant activity  
 EV-TF activity might be increased by freeze thawing [25]  
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D. Problem of contact activation? 
There was no consensus whether contact activation should be considered a pre-analytical 
problem for the investigation of procoagulant EVs.  
Considerations for future recommendations 
 Preparation of platelet-depleted plasma by double-centrifugation reduces the risk of 
platelet contamination 
 Make assays as simple as possible 
 Use available blood collection tubes 
 Routine use of the factor XIIa inhibitor corn trypsin inhibitor or equivalents are not 
recommended  
E. Need for a tissue factor standard? 
All participants confirmed the need for a TF standard to standardize PCA measurements.  
“Innovin” is currently used but suffers from an unknown concentration of TF, batch to batch 
variation, and shipment/storage effects. A possible standard could be the use of TF-EVs from 
cultured cells.  
F. Measurement of EV-TF activity and antigen? 
While one participant was in favour of combining assays for the quantification of TF 
exposing EVs, other participants had objections. The major objection is the lack of 
convincing results demonstrating the presence of TF on EVs by flow cytometry. This lack is 
likely due to a limited number of TF epitopes per EV, quality of available antibodies, 
blockade of TF with factor VII and tissue factor pathway inhibitor, and the lack of sensitivity 
of current flow cytometers to detect dim (low fluorescent) EVs.  
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G. Need for standard operating procedures and multi-centre studies? 
All participants agreed that standard operating procedures (SOPs) need to be developed and 
tested. A methodological interlaboratory comparison study seems timely. Performing multi-
centre studies is considered relevant by all participants. 
Workshop proposal to compare sensitivity and specificity of assays to measure tissue factor 
coagulant activity associated with extracellular vesicles in human plasma 
Françoise Dignat-George suggests to organize 2 workshops to compare the sensitivity and 
specificity of assays that measure the coagulant activity of TF-exposing EVs in human 
plasma.  
In the first year core laboratories will prepare plasma samples that will serve as TF negative- 
and TF positive standards. Aliquots of 5 - 10 different platelet-depleted plasma samples from 
healthy donors will serve as TF negative standards, as these samples will be from non-
stimulated blood, and therefore are expected to contain no detectable EV-TF activity. TF 
positive standards will be generated form blood samples that will be either stimulated with 
lipopolysaccharide [LPS] to trigger TF expression by monocytes followed by the release of 
TF-EVs, or, alternatively, the blood or plasma samples will be spiked with TF-EVs from 
various sources. The core laboratories will characterize the prepared plasma samples for 
stability and homogeneity during storage for particle size distribution, cellular origin and 
coagulant activity of EVs by nanoparticle tracking analysis and/or tunable resistive pulse 
sensing, flow cytometry, and PS-dependent and/or TF-dependent coagulation assays. The 
characterized samples will be distributed to participating laboratories. Participating 
laboratories will describe their methods to determine TF antigen and activity, and in the 
second year, will analyse the provided samples. Data will be sent to core laboratories. 
Sensitivity is evaluated by measuring the ability of the various assays to discriminate platelet-
depleted plasma (TF deficient) from blood stimulated with LPS or spiked with TF-EVs. 
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Specificity will be evaluated by measuring the signal of platelet-depleted plasma spiked with 
(i) similar concentrations of TF-EVs or “knock-out” TF-EVs, and (ii) with activators or 
inhibitors of contact activation.  Regular assay performance, including reproducibility and 
linearity, will be recorded. The final outcome will be reported to the SSC on Vascular 
Biology of the ISTH, and will be submitted for publication to the Journal of Thrombosis and 
Haemostasis.  
 
Addendum 
R. Niewland drafted the manuscript, which was reviewed, edited, and approved by all 
authors. The manuscript is based on (i) a questionnaire, which was drafted by R. Nieuwland 
and J. Thaler, and edited by all authors and (ii) a round table discussion, which all authors 
attended at the 64
th
 Annual SSC Meeting of the ISTH (Dublin, Ireland). 
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